| INTRODUCTION
Kidney transplantation is the best treatment for most patients with end-stage kidney disease. However, despite improvements in shortterm transplant survival, long-term rates have not improved in recent decades. 1 Calcineurin inhibitors (CNIs, eg, tacrolimus) are central to modern immunosuppression but are associated with graft fibrosis and atrophy, worsening transplant function, and long-term transplant failure. 2, 3 Immunosuppression strategies that minimize CNI exposure may be expected, therefore, to reduce the rate of late transplant failure. 4 Inhibitors of the mammalian target of rapamycin pathway (mTORi, eg, sirolimus) were first tested in various strategies to replace CNI; however, de novo use (ie, from the time of transplantation) is associated with complications, 5, 6 and a large trial of late (ie, >6 months posttransplantation) conversion from CNI-based therapy found no improvement in subsequent function. 7 In contrast, early (ie, within 6 months of transplantation) conversion to mTORi has been shown in some (but not all) trials to improve transplant function compared with remaining on cyclosporine-based immunosuppression. [8] [9] [10] [11] [12] Another potential benefit of conversion to mTORi is a reduction in the risk of malignancy posttransplantation (especially skin cancer). [13] [14] [15] However, a recent meta-analysis suggested that sirolimus may be associated with an increased risk of all-cause mortality. 15 mTORi have more favorable effects than CNIs on tolerogenic T regulatory cells, and this effect may be most notable after alemtuzumab-based induction therapy. 16 A series of kidney transplant recipients treated with alemtuzumab, and elective conversion to sirolimus 6 months later reported good results, 17 and it was hypothesized that the combination with alemtuzumab induction treatment enabled patients to become established on maintenance sirolimus without the problems that had limited previous studies (including increased rejection). No previous randomized controlled trials have compared mTORi with CNIs in combination with either alemtuzumab-or basiliximab-based induction therapy: this is the overall issue addressed by the 3C Study. The first planned analysis of the 3C study, comparing the immediate effects of the 2 induction treatments, has been reported previously and showed a highly significant halving of rejection in patients treated with alemtuzumab. 18 In the current report, the results of the sirolimus-versus tacrolimus-based maintenance therapy randomization are presented.
| METHODS

| Trial design and participants
Details of the 3C Study methods have been reported previously, 18, 19 and the trial design is summarized in Figure 1 . The data analysis plan was finalized and published online at www.3cstudy.org in advance of any unblinded analyses being conducted and is available in the Supplementary Appendix. Approval from a national research ethics committee was obtained before enrolment. The study is registered at ClinicalTrials.gov, NCT01120028 and ISRCTN88894088. was assessed and written informed consent was obtained. Induction therapy was randomly allocated (either alemtuzumab or basiliximab based), and all participants received tacrolimus and mycophenolate (and prednisolone if assigned basiliximab). Participants with a functioning transplant between 5 and 7 months after transplantation were eligible to participate in this comparison of tacrolimus-versus sirolimus-based maintenance therapy with 2 exclusion criteria: (i) a proven rejection episode in the previous month and (ii) proteinuria in excess of 800 mg daily (estimated by spot urine protein:creatinine ratio) ( Figure 1 ).
| Randomization and blinding
Eligible and consenting participants were allocated the study treatment through minimized randomization (see Supplementary Appendix). 20 
| Procedures
Participants were to be reviewed at 3 and 6 months after maintenance therapy randomization. At each follow-up visit, blood pressure and weight were to be measured, and blood and urine samples were in Wales (for information about any hospitalizations). All information from these registries was provided blinded to treatment allocation.
| Statistical analysis
Analysis of covariance (ANCOVA) was used to compare mean levels of eGFR at 18 months between sirolimus-and tacrolimus-allocated patients, with adjustment for each individual's eGFR at randomization into the maintenance phase of the trial. While it was hoped that about 500 of the 800 patients originally randomized in the induction phase of the trial would be willing and eligible to be rerandomized in the maintenance phase, the randomization of 400 patients in the maintenance phase, together with chosen ANCOVA analysis, still provided >90% power at 2-sided P = .05 to detect a 5 mL/min/1.73 m 2 difference in eGFR at 18 months. The few participants with eGFR missing at 18 months had their value imputed using multiple imputation, with the results across imputations combined using the methods of Rubin. 22 Time-to-event analyses prespecified log-rank methods to calculate the average event rate ratio (RR), 95% confidence intervals (CIs), and its associated 2-sided P value. However, for biopsy-proven acute rejection (BPAR), the RR was subsequently estimated instead by the hazard ratio from a Cox proportional hazards regression model (because it was large and the log-rank "1-step" estimate of the RR increasingly underestimates the true RR as it becomes more extreme). 23 All analyses were done according to the intention-to-treat principle among all randomized participants, and all P values are 2-sided. 23, 24 To investigate the possibility that sirolimus may have been of benefit among participants who could tolerate it, 2 types of exploratory analyses were conducted. First, we conducted a nonrandomized comparison of eGFR among those participants who remained compliant with their allocated maintenance therapy at 18 months after randomization, before and after adjustment for baseline characteristics. Second, an exploratory analysis preserving the randomized comparison used a score to predict noncompliance with sirolimus from baseline characteristics that was constructed by using standard logistic regression among the participants assigned sirolimus. This was then applied to all participants (including those assigned tacrolimus) to allow stratification by tertiles of risk of noncompliance. A standard test for trend was performed to explore whether the effect of sirolimus varied by risk of noncompliance and, in particular if there was any evidence to suggest that sirolimus was more beneficial among participants at the lowest risk of noncompliance. Unless stated otherwise, all analyses were prespecified. Analyses were done with SAS version 9.3 (SAS Institute, Cary, NC) and R version 2.11.1 (www.R-Project.org). 
| Role of the funding source
| RESULTS
Of the 852 participants who were randomly assigned to either alemtuzumab-or basiliximab-based induction therapy, 820 were transplanted. Between April 2011 and July 2013, 394 of these participants were randomly assigned to sirolimus-based therapy versus tacrolimus-based therapy ( Figure 1 ). The most common reasons for participants not entering the maintenance therapy comparison were managing physician decision and patient preference (Table S1 ). Mean age at this randomization was 52 years (SD 13), 264 (67%) were male, and 347 (88%) were white (Table 1) . Two-thirds of participants were receiving at least 720 mg daily of mycophenolic acid and one-third were on prednisolone at the time of randomization (Table S2) . T A B L E 1 (Continued) 8.7 (4.0) ng/mL and 6.9 (2.1) ng/mL at 3 and 18 months, respectively (Table S5A ). Among participants assigned tacrolimus-based therapy and still receiving it, the mean concentration was 7.4 (4.2) ng/mL and 7.0 (2.2) ng/mL at 3 and 18 months, respectively. Exploratory analyses showed that other immunosuppression did not differ during the period of follow-up when such data were collected (up to 6 months postrandomization; Table S5B ).
At 18 months after randomization, the mean (SE) eGFR among participants assigned sirolimus-based therapy was 53.7 (0.9) compared with 54.6 (0.9) mL/min/1.73 m 2 among those assigned tacrolimusbased therapy (P = .50; Figure 2 Figure 3 ). Post-hoc analyses show this relative risk was similar among participants assigned alemtuzumab-based and basiliximab-based induction therapy (P for heterogeneity = .47) and
was similar regardless of baseline dose of MPA (P for trend = .94) or prednisolone (P for heterogeneity = .65). Exploratory analyses indicated that the mean 18-month eGFR of participants who experienced rejection was 7.4 (7.1) mL/min/1.73 m 2 lower among those assigned sirolimus compared with those assigned tacrolimus, whereas it was 0.5
(1.3) mL/min/1.73 m 2 higher among those who did not experience rejection. We saw no significant difference in transplant failure: 8 (4.1%) versus 4 (2.0%) ( (Table S8 ). Participants assigned sirolimus-based therapy also had significantly more proteinuria (difference in geometric means at 6 months 201% [75% to 418%]; P < .001) and higher cholesterol and triglyceride concentrations at 6 months (Table S9 ).
| DISCUSSION
The 3C Study was set up to investigate whether it is feasible to establish patients on long-term CNI-free immunosuppression and whether this is associated with reduced graft attrition (using kidney function [eGFR] as a surrogate in this analysis). Based on previous work, we hypothesized that the use of alemtuzumab-based induction therapy might enable patients to be established on sirolimusbased therapy without the complications (wound healing, rejection, mouth ulceration, pneumonitis) that have limited such strategies previously. 17 Our findings suggest that elective conversion to sirolimus at about 6 months after kidney transplantation does not improve subsequent transplant function and carries significant risks of rejection and infection and that this detriment applies even in the context of the (previously demonstrated) benefits of alemtuzumab induction therapy. We included a broad range of different types of participant and recruited about one-eighth of all kidney transplant recipients transplanted in the participating centers during the recruitment period.
These results are likely therefore to be relevant to a broad population of patients.
Our findings are discrepant with previous published trials that have explored CNI avoidance strategies. However, with 394 participants in this second randomization, the 3C Study is the largest such trial (almost twice as large as the next largest trial using sirolimus).
It is notable that most previous studies have used cyclosporinebased therapy as the comparator (in part because this was previously the regimen approved by the US Food and Drug Administration).
However, tacrolimus is now by far the most widely used CNI in the United States and worldwide and -in conjunction with mycophenolate -is the clinically most relevant comparator. The only previous trial comparing a sirolimus-based strategy with a tacrolimus-based strategy also found no benefit. 25 It is possible that cyclosporine is more nephrotoxic than tacrolimus or that, historically, cyclosporine was used at higher equivalent concentrations than tacrolimus is used in current practice. In the Elite-SYMPHONY study, low-dose tacrolimus (target trough concentration 3-7 ng/mL, similar to that used in the 3C Study) provided better transplant function at 1 year compared with standard-or low-dose cyclosporine. 5 Consistent with this is a recent report from the Westmead Hospital, Sydney, which found less evidence of nephrotoxicity in serial protocol kidney biopsy samples taken from kidney-pancreas transplant recipients between 1999 and 2012 (an era when tacrolimus was the predominant CNI) compared with those taken between 1987 and 2000 (when cyclosporine was used). 3 This has significant implications for the interpretation of data from clinical trials that have compared novel immunosuppressants with cyclosporine rather than tacrolimus. 9, 26 Whether this is drug specific or dose specific, the way in which tacrolimus is currently used appears to be substantially less nephrotoxic than older CNI regimens.
Another possible reason for the apparent discrepancy was that adherence to sirolimus-based therapy was low in the 3C Study, with only half of all participants allocated sirolimus still taking it 18 months after randomization. The adherence was somewhat worse than we had anticipated but nonetheless in keeping with previous studies. 8, 25, [27] [28] [29] [30] The low adherence level in the 3C Study reduces the sensitivity of the trial to detect a true difference in transplant function but also, importantly, means F I G U R E 3 Life-table plot of the effect of allocation to sirolimus-based maintenance therapy on any biopsyproven rejection that estimates of the hazards may be less than would be observed with full adherence. It is possible that the development of donor-specific antibodies (DSAs) may be an important determinant of long-term transplant function, 31 but we did not measure DSAs in this trial.
One of the underlying hypotheses for the 3C Study was that the use of lymphocyte-depleting induction therapy might facilitate the conversion to sirolimus at 6 months, as suggested by a small pilot study. 17 However, we found no evidence that sirolimus-based maintenance therapy was more effective after alemtuzumab-based than nondepleting basiliximab-based induction therapy. Alemtuzumab has been suggested to induce a state of "prope" (near) tolerance 32 and, in combination with sirolimus, induces more tolerogenic regulatory T cells. 16 Despite favorable results of the pilot study, 17 we found no effect on transplant function: this is consistent with the findings of small trials using histologic outcomes. 16 Our finding that allocation to sirolimus-based maintenance therapy substantially increased the risk of BPAR is also consistent with findings in previous studies. 8, 12 We investigated the relevance of compliance to these results with 2 exploratory analyses. The first of these yielded an apparent difference in eGFR between the 100 participants who remained compliant with sirolimus and the 180 participants who remained compliant with tacrolimus. This result is, of course, of uncertain relevance because those who discontinued allocated sirolimus (the nature of which was known because the trial was not blinded) may have done so for adverse effects whose risk of occurrence may be correlated with renal function. Such an analysis may not be a reliable indication, therefore, of the differential effects of sirolimus on renal function (as compared with tacrolimus). We explored this further and found weak evidence that participants more likely to remain adherent to sirolimus might derive greater benefit from allocation to the sirolimus arm. Taken together, the results from these 2 analyses should perhaps still be considered only as hypothesis generating and require independent confirmation.
Infections were also more common with sirolimus-based therapy.
There was no overall effect on opportunistic infections: other studies have suggested that sirolimus may interfere with viral replication and therefore reduce the incidence of cytomegalovirus infections. 33, 34 We observed no benefit (or hazard), but there were too few such infections in the 3C Study to make robust inferences. The excess in all serious infections was due to a higher rate of nonopportunistic infections (notably respiratory and gastrointestinal infections) among participants assigned sirolimus-based therapy. Given the overlap with known symptomatic side effects of sirolimus (eg, pneumonitis) it is possible that misclassification (ie, attribution of symptoms to an infective cause rather than to a direct drug effect) explains some of this excess. However, such symptoms would not typically resolve without cessation of sirolimus.
We did not observe any effect on cancer incidence. Sirolimus has been shown to inhibit the development of nonmelanoma skin cancer and other cancers. [13] [14] [15] 35 However, most posttransplantation malignancies take several years to develop, and the time horizon for these analyses was likely to be too early to observe any such benefit.
Furthermore, this trial alone is too small to detect plausible effects on cancer incidence.
We observed the known effects of sirolimus on proteinuria. 36 The mechanism of sirolimus-induced proteinuria is unclear, 37 but proteinuria is a recognized risk factor for subsequent transplant failure. 38 With only 12 transplant failures during the period of observation, our power to detect an effect on this is extremely limited, but 2 metaanalyses found no effect of sirolimus on transplant survival. 11, 15 The increase in non-high-density lipoprotein cholesterol of 0.5 mmol/L would be consistent with a 10% increased risk of major vascular events. 39 Posttransplantation diabetes mellitus was nonsignificantly more common among participants assigned sirolimus-based therapy, so overall the impact of sirolimus on cardiovascular risk was adverse. We observed no significant effect on major vascular events or allcause mortality, but with only 23 and 20 such events, respectively, the study's power was negligible. A recent meta-analysis has suggested that sirolimus is associated with an increased risk of death. 15 However, this effect was only marginally statistically significant in unadjusted analyses (P = .04), and most of the data were from trials in which sirolimus was used de novo and not following elective conversion as we did in our trial.
A limitation of the 3C Study was that just under half of all participants recruited at the time of transplantation entered this comparison. However, the baseline characteristics of these participants were similar to those of the overall trial cohort, suggesting that this result is likely to be generalizable. Information on concomitant immunosuppression and reasons for stopping were collected for only 6 months after randomization. A further limitation of the 3C Study was the requirement for it to be open label. However, the primary outcome (eGFR at 18 months after randomization) was collected by linkage with the UK Renal Registry, which, in turn, collects its data through routine extraction from hospital databases, making it highly unlikely that the values entered would be biased with respect to treatment allocation. Although these analyses were based only on 18-month follow-up, the 3C Study has established linkage with appropriate national registries, so longer-term follow-up will be conducted in a cost-effective manner and may yield informative results.
Our findings suggest that compared with continuation of a tacrolimus-based regimen, elective conversion to sirolimus-based maintenance therapy does not improve transplant function 18 months later (regardless of induction therapy) and is associated with significant hazards of rejection and infection.
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